What is the current stock price of NeuroPace, Inc. (NPCE)?

As of the latest market data, NeuroPace, Inc. (NPCE) is trading at $17.06. The stock has seen a gain of 2.28% today.

Does NeuroPace, Inc. (NPCE) pay a dividend?

Based on current data, NeuroPace, Inc. does not have a confirmed active dividend policy.

What is the market cap of NeuroPace, Inc.?

The current market capitalization of NeuroPace, Inc. (NPCE) is approximately unavailable.

NPCE

NeuroPace, Inc.·Healthcare

17.06

2.278%(+0.38)

Close Price

22.00

28.957%(+4.94)

Pre-Market

Last Updated: — ET

52W L: $7.5652W H: $19.60

NPCE NEWS

zacks.com

18h ago

Is NPCE Stock a Buy in 2026 After DIXI Exit and Margin Lift?

NeuroPace exits DIXI, doubles down on RNS as Q1 narrows losses and lifts 2026 guidance, Medicare and pricing actions support margins.

zacks.com

18h ago

NPCE Explains How NeuroPace's RNS System Makes Money

NeuroPace tightens focus on its RNS epilepsy implant, exits DIXI distribution and pushes AI + cloud workflow tools as 2026 revenue guidance rises.

zacks.com

19h ago

NeuroPace NPCE and the Next Wave of AI-Driven Epilepsy Care

NPCE bets on AI ECoG Assistant and cloud upgrades as it refocuses on RNS, while IGE label review and coverage timing loom.

zacks.com

May 13

NPCE Stock Gains on Q1 Earnings & Revenue Beat, 2026 Outlook Raised

NeuroPace raises revenue guidance for 2026 after Q1 sales beat estimates and losses narrow, driven by strong RNS System growth.

seekingalpha.com

May 12

NeuroPace, Inc. (NPCE) Q1 2026 Earnings Call Transcript

marketbeat.com

May 12

NeuroPace Q1 Earnings Call Highlights

NeuroPace NASDAQ: NPCE raised its 2026 revenue outlook after reporting first-quarter results that management said reflected continued demand for its RNS System and improving commercial execution across epilepsy treatment centers.

Company Profile

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.

Sector

Healthcare

Industry

Medical - Devices

Employees

184

IPO Date

2021-04-22

Beta

1.93

Websitewww.neuropace.com↗